Literature DB >> 15762038

The cost of immunosuppressive therapies currently used in patients with thyroid eye disease.

G E Krassas1.   

Abstract

Thyroid eye disease (TED) is an inflammatory condition of the orbit occurring in patients with autoimmune disease. In patients with mild TED, the most important therapeutic measure is reassurance. In severe cases, immunosuppressive therapy is the mainstay of treatment and around 10 immunosuppressive regimens have been suggested and used in such patients so far. The efficacy of these regimens varies according to the number of studies that have addressed these issues. "Response" to the treatment is also variably defined. However, to the best of our knowledge, no study has reported on the cost of immunosuppressive therapy in such patients. The aim of this study was mainly to provide information concerning the cost of different immunosuppressive regimens that patients with active thyroid ophthalmopathy undergo in different European countries. We have shown that the cheapest treatment is oral glucocorticoids (GC) and the most expensive is iv immunoglobulins. Cyclosporine is the second cheapest treatment. Radiotherapy plus oral GC have a cost between 850-3200 Euro; while SS analogues (SS-a) are expensive with a cost between 5000-10000 Euro. However, it is worth noting that the patients studied so far in this group were only few and most of them selected on a basis of a positive octreoscan, the cost of which has to be considered when choosing this type of treatment. Germany is by far the most expensive country as regards the costs of the main remedies, whereas Greece is the cheapest. Denmark is the most expensive country concerning radiotherapy, while Germany is the cheapest.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15762038     DOI: 10.1007/BF03347533

Source DB:  PubMed          Journal:  J Endocrinol Invest        ISSN: 0391-4097            Impact factor:   4.256


  19 in total

Review 1.  Immunosuppressive therapy in patients with thyroid eye disease: an overview of current concepts.

Authors:  G E Krassas; A E Heufelder
Journal:  Eur J Endocrinol       Date:  2001-04       Impact factor: 6.664

Review 2.  Graves' ophthalmopathy: current concepts regarding pathogenesis and management.

Authors:  H B Burch; L Wartofsky
Journal:  Endocr Rev       Date:  1993-12       Impact factor: 19.871

Review 3.  Endocrine ophthalmopathy: current ideas concerning etiology, pathogenesis, and treatment.

Authors:  D H Jacobson; C A Gorman
Journal:  Endocr Rev       Date:  1984       Impact factor: 19.871

Review 4.  Management of Graves' ophthalmopathy: reality and perspectives.

Authors:  L Bartalena; A Pinchera; C Marcocci
Journal:  Endocr Rev       Date:  2000-04       Impact factor: 19.871

5.  Ciclosporin and prednisone v. prednisone in treatment of Graves' ophthalmopathy: a controlled, randomized and prospective study.

Authors:  G Kahaly; J Schrezenmeir; U Krause; B Schweikert; S Meuer; W Muller; R Dennebaum; J Beyer
Journal:  Eur J Clin Invest       Date:  1986-10       Impact factor: 4.686

Review 6.  Somatostatin analogues in the treatment of thyroid eye disease.

Authors:  G E Krassas
Journal:  Thyroid       Date:  1998-05       Impact factor: 6.568

7.  Orbital cobalt irradiation combined with retrobulbar or systemic corticosteroids for Graves' ophthalmopathy: a comparative study.

Authors:  C Marcocci; L Bartalena; M Panicucci; C Marconcini; F Cartei; G Cavallacci; M Laddaga; G Campobasso; L Baschieri; A Pinchera
Journal:  Clin Endocrinol (Oxf)       Date:  1987-07       Impact factor: 3.478

Review 8.  The side-effects of ciclosporine-A and tacrolimus.

Authors:  M J Mihatsch; M Kyo; K Morozumi; Y Yamaguchi; V Nickeleit; B Ryffel
Journal:  Clin Nephrol       Date:  1998-06       Impact factor: 0.975

9.  Orbital cobalt irradiation combined with systemic corticosteroids for Graves' ophthalmopathy: comparison with systemic corticosteroids alone.

Authors:  L Bartalena; C Marcocci; L Chiovato; M Laddaga; G Lepri; D Andreani; G Cavallacci; L Baschieri; A Pinchera
Journal:  J Clin Endocrinol Metab       Date:  1983-06       Impact factor: 5.958

10.  Plasma glycosaminoglycans in endocrine ophthalmopathy.

Authors:  G Kahaly; C Hansen; J Beyer; R Winand
Journal:  J Endocrinol Invest       Date:  1994-01       Impact factor: 4.256

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.